

Mark Poznansky, MD is Associate Professor of Medicine at Harvard Medical School, Attending Physician in Infectious Diseases Medicine and Director of the Vaccine and Immunotherapy Center (VIC) at MGH. He is the discoverer of fugetaxis, the principle of immuno-repulsion that forms the basis of the products developed by Aperisys, Inc. His laboratory defines molecular mechanisms for novel immune processes and explores the relevance of these mechanisms for novel approaches to vaccines and immunotherapies for cancer, infectious diseases and diabetes. Dr. Poznansky and his team at VIC have focused on the translation of novel vaccines and immunotherapies from discovery to first-in-human studies and is funded by the JDRF, NIH, DOD and philanthropy.

Dr. Poznansky is the scientific founder of a number of spin-off biotech companies including Celtaxsys and ACTx. He is also a consultant to K2 Therapeutics and a former scientific consultant to Novelos and the St. Joseph's Translational Research Institute in Atlanta. Dr. Poznansky also serves on the Commercialization Council and co-chairs the Department of Medicine Innovation Taskforce at MGH.